Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...
Learn more Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at ...
Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
A trio of deals from Eli Lilly, Servier, and Avenzo highlights continued industry investment in rare diseases and oncology, ...
Zacks Investment Research on MSN
Edgewise Therapeutics stock hits record high on $2.65B Servier deal
Shares of Edgewise Therapeutics EWTX jumped 17.9% on Monday, closing at an all-time high after the company announced a ...
Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...
Investor's Business Daily on MSN
How Edgewise sweetened its coffers by $1.55 billion, and removed a key overhang
Edgewise Therapeutics stock rocketed Monday after Servier agreed to buy the biotech's muscular dystrophy business for up to $2.65 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results